secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001104659-23-060756
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics Q1 2023 revenue $6.2M, net loss $26.7M; KORSUVA vial demand doubles
--------------------------------------------------------------------------------

- Total revenue $6.2M (up from $4.8M YoY); net loss $26.7M ($0.49/sh) vs $27.7M ($0.52/sh) in Q1 2022.
- KORSUVA injection net sales $5.7M; vial shipments to dialysis centers 45,720, more than doubling QoQ.
- Cash, equivalents and securities $123.4M at March 31, 2023, down from $156.7M; cash runway into 2H24.
- Oral difelikefalin: KIND 1 atopic dermatitis Part A readout on track for 4Q23; KICK CKD topline 2H24; KOURAGE NP Part A 2H24.
- Kapruvia launched in four European countries; Japan PMDA decision expected 2H23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923060756/0001104659-23-060756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923060756/tm2315680d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-060756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer